HSV-1 and HSV-2 are two distinct types of herpes simplex virus. 124 They are not fixed labels for body location: HSV-1 commonly causes oral herpes and can cause genital herpes, while HSV-2 mainly causes genital herpes and can also infect the mouth. 247
If the infection is genital, type has a practical meaning. Genital HSV-2 generally recurs and sheds more often than genital HSV-1. 13456 That is a group-level pattern, not a personal forecast. Either type can cause noticeable symptoms, no recognized symptoms, recurrences, shedding without a visible sore, and transmission. 123456
A result is most useful when you know both the type and the site. A positive typed lesion test can connect HSV-1 or HSV-2 to the sampled sore. 134 Blood tests look for antibodies instead: HSV-1 antibody does not show whether infection is oral or genital, while CDC generally interprets an appropriately confirmed type-specific HSV-2 antibody result as evidence of anogenital, meaning genital or anal, infection. 1 Blood testing does not tell you when infection happened, who transmitted it, or whether shedding is happening now. 1
The shortest useful comparison
| Question | HSV-1 | HSV-2 |
|---|---|---|
| Usual pattern | Most often oral, but it can be genital. 234 | Most often genital; oral infection is possible but oral reactivation is uncommon in the checked evidence. 247 |
| What a blood result locates | An HSV-1 antibody result does not distinguish oral from genital infection. 1 | An appropriately confirmed antibody result generally implies anogenital infection in CDC guidance, but it does not locate a past lesion or show current shedding. 1 |
| At the genital site | Recurrences and shedding are less frequent on average and shedding falls during the first year after a first episode. 1345 | Recurrences and shedding are more frequent on average, including among some people who do not recognize symptoms. 1346 |
| Treatment | The same core antiviral medicines are available. Suppressive treatment may be considered for frequent genital HSV-1 recurrences, but prevention of partner transmission with suppression has not been studied. 124 | The same core antiviral medicines are available. CDC provides episodic and suppressive regimens for recurrent genital HSV-2 and cites transmission-reduction evidence from a specific symptomatic partner population. 124 |
Type and site are separate facts
It is more accurate to think in combinations than slogans:
- Oral HSV-1 is the most common oral pattern. 24
- Genital HSV-1 is well established and can follow oral-genital contact. 1234
- Genital HSV-2 is the most common recognized HSV-2 pattern. 24
- Oral HSV-2 is possible, but oral reactivation was uncommon in the checked primary study. 47
The body site helps explain which skin or lining tissue can have symptoms or shed virus. The type helps with counseling about what tends to happen at that site. Neither replaces the other. 134
What a lesion test can show that a blood test cannot
A positive type-specific nucleic-acid amplification test, usually called NAAT or PCR, or a positive culture from a lesion identifies HSV-1 or HSV-2 in the lesion that was sampled. 134 If a genital sore tests positive for HSV-1, that establishes genital HSV-1 at that sampled site. 134
Type-specific blood testing looks for antibodies rather than virus in a lesion:
- HSV-1 antibody supports previous HSV-1 infection but cannot distinguish oral from genital infection. 1
- Appropriately confirmed HSV-2 antibody is generally interpreted by CDC as evidence of anogenital infection because nearly all HSV-2 infections are sexually acquired. It does not identify when infection happened, who transmitted it, a past lesion's exact location, or current shedding. 1
- HSV-1 and HSV-2 antibodies can both be present. Having HSV-1 does not prevent a person from acquiring HSV-2. 12
If you are trying to choose a test, understand timing, or make sense of a low-positive or unconfirmed result, read the full HSV testing guide. This page does not repeat those assay and confirmation details.
Symptoms do not identify the type
A first genital episode caused by HSV-1 can look like one caused by HSV-2. Symptoms and appearance alone do not reliably identify the type, and many infections are mild, atypical, or not recognized at all. 1234
Type becomes more informative over time because the average pattern of genital recurrences and shedding differs. 134 It does not guarantee how severe a first episode will be or how one person will feel later.
If a new blister, ulcer, or sore is present, seek assessment while it can still be sampled. Get individual care promptly for severe illness, eye pain or vision changes, neurologic symptoms, significant immune suppression, or possible new genital HSV during pregnancy. 124
How genital recurrence and shedding generally differ
A recurrence is a later symptomatic episode after HSV reactivates. Shedding means virus is released or detected at skin or mucosal surfaces, the moist tissue lining areas such as the mouth or genitals. Shedding can happen with a visible lesion or without one. 123456
Across current CDC, European, and NIH guidance, the direction of the comparison is consistent: genital HSV-2 recurs and sheds more often than genital HSV-1. Genital HSV-1 shedding also drops quickly during the first year after a first episode. 1345
That comparison has limits:
- It describes averages across groups, not a timetable for one person.
- It does not mean everyone with genital HSV-2 has frequent symptoms. HSV-2 shedding occurs in people with and without a recognized symptom history. 16
- It does not mean genital HSV-1 is symptom-free or non-transmissible. Shedding was detected with and without lesions in the first-episode HSV-1 cohort. 5
- Time since infection, symptom history, immune status, antiviral use, and study design can change what a shedding number means. 13456
What the studies measured
The numbers below describe specific cohorts. They should not be read as your personal shedding or transmission percentage.
| Evidence | Population and timeframe | Finding | Limit |
|---|---|---|---|
| First-episode genital HSV-1 cohort | 82 people with laboratory-documented first-episode genital HSV-1, without HIV or current pregnancy; daily genital swabs during 30-day sessions around 2 and 11 months after the first episode. 5 | HSV-1 was detected on 275 of 2,264 genital-swab days (12.1%) around 2 months and 122 of 1,719 days (7.1%) around 11 months. 5 | It did not measure partner transmission, and the sampling windows do not describe every day of the first year. 5 |
| Genital HSV-2 shedding cohort | 498 immunocompetent HSV-2-seropositive people in prospective studies; at least 30 days of daily genital swabs; 410 had recognized symptomatic infection and 88 were classified as asymptomatic. 6 | HSV-2 was detected on 4,753 of 23,683 days (20.1%) in the recognized symptomatic group and 519 of 5,070 days (10.2%) in the asymptomatic group. 6 | Infection timing varied, there was no HSV-1 comparison arm, and it did not measure partner transmission. 6 |
| Genital recurrence cohort | 664 people with genital herpes followed at a university research clinic for at least 14 months; more than 12,000 reported or observed recurrences were analyzed. 8 | For newly acquired infection, the median in the first follow-up year was 1 recurrence for HSV-1 and 5 for HSV-2. Rates fell in the second year for both types, but individual courses varied. 8 | This older clinic cohort cannot predict one person's number of recurrences. 8 |
The two shedding studies were not a head-to-head comparison. Their enrollment, infection timing, symptom histories, and sampling periods differ. Dividing one percentage by the other would create a result that neither study measured. 56
What is known and not known about transmission
Both HSV-1 and HSV-2 can be transmitted when no sore is visible. 23 Active sores are a higher-risk period, but the absence of a sore does not mean no transmission can occur. 23
Type and site still matter because they affect how often virus is detected at that site. 1356 But a shedding-day percentage is not a per-act or annual transmission probability. 356 Exposure route, the body sites involved, symptoms, time since infection, partner susceptibility, barrier use, and antiviral use all affect the real situation. 13
The direct prevention evidence is uneven. Daily valacyclovir has evidence for reducing transmission in a studied population of heterosexual couples in which one partner had symptomatic genital HSV-2 and the other did not have HSV-2. CDC and NIH state that suppressive therapy to prevent genital HSV-1 transmission has not been studied. 14
For the fuller evidence on symptoms, condoms, daily suppression, partner studies, and why online annual percentages cannot become one couple's forecast, read what changes genital herpes transmission risk.
Do treatment options differ by type?
The core antiviral medicines overlap: acyclovir, valacyclovir, and famciclovir are used for HSV. For a first clinical episode of genital herpes, CDC recommends antiviral medication and does not split its regimens by HSV type. 12
Type can change the later treatment conversation. CDC provides episodic and suppressive treatment options for recurrent genital HSV-2 and cites transmission-reduction evidence for a specific symptomatic partner population. For genital HSV-1, CDC says suppressive treatment should generally be reserved for frequent recurrences through shared decision-making, and its effect on partner transmission has not been studied. 14
That does not choose a treatment for you. Site, first versus recurrent episode, symptom severity, recurrence burden, pregnancy, immune status, other medicines, and whether the goal is symptom control or transmission reduction all matter. 134 Read the dedicated HSVHQ Herpes Treatment guide; individual treatment decisions should be made with a qualified clinician rather than inferred from type alone.
Is one type better or worse?
Not as a universal judgment. If the narrow question is the usual long-term pattern after a genital infection, HSV-1 generally has fewer recurrences and less shedding than HSV-2. 13458 That can be meaningful. It is not a promise that genital HSV-1 will be easy, symptom-free, or impossible to transmit. 1345
HSV-2 is not a forecast of constant outbreaks either. Many people do not recognize symptoms, recurrence frequency varies, and rates can change over time. 1268
The responsible comparison is specific: type changes some probabilities and some evidence behind management. It does not measure the seriousness of one person's symptoms, the effect on their relationships, or their worth.
Can someone have both HSV-1 and HSV-2?
Yes. Having HSV-1 does not prevent HSV-2 acquisition, so one person can have both types. 12
The result still needs context. Two positive blood-antibody results do not show where HSV-1 is located, when either infection occurred, or whether either site is shedding now. A typed lesion result can establish more about the sampled site. 1
What information do you need after learning the type?
Try to separate what is known from what is still unknown:
- Which test produced the result? A typed lesion NAAT/PCR, culture, or blood antibody test does not answer the same question. 134
- Which body site was established? Do not assign an HSV-1 blood result to the mouth or genitals without site evidence. 1
- Was an HSV-2 blood result appropriately confirmed? The assay, numeric value when reported, and confirmation details belong in the Testing guide. 1
- What symptoms have occurred, and when? Symptoms do not reveal type, but they affect testing opportunities and treatment conversations. 1234
- How long has a genital first episode been recognized? Time matters to the genital HSV-1 shedding evidence, but it still does not create a personal forecast. 15
- What is the practical question now? Treating a current episode, considering suppression, understanding a partner's result, or reducing transmission calls for different evidence. 134
- Is pregnancy, significant immune suppression, eye involvement, neurologic illness, or severe disease part of the situation? Those contexts need individual medical assessment. 124
It is acceptable for some answers to remain unknown. A type label should not be used to invent the missing site, timing, source, symptom course, or personal transmission percentage.
Where the fuller answer lives
- Use the HSV testing guide for lesion swabs, blood-test timing, low-positive HSV-2 results, confirmation, and what a result can and cannot establish.
- Use the genital herpes transmission guide for routes, asymptomatic shedding, symptoms, condoms, daily suppression, partner studies, and the limits of transmission percentages.
- Use the dedicated HSVHQ Herpes Symptoms guide. A new or concerning lesion deserves clinical assessment rather than diagnosis from a comparison page.
- Use the dedicated HSVHQ Herpes Treatment guide. Treatment depends on the site, episode, health context, and goal, not only the HSV type.
Evidence and sources
Evidence scope: Current CDC, WHO, European, and NIH guidance; prospective cohorts of first-episode genital HSV-1 shedding and genital HSV-2 shedding, a long-term genital recurrence cohort, and a research-clinic database analysis of oral HSV-2 isolation.
Important limitations: The genital HSV-1 and HSV-2 shedding studies are not head-to-head and do not measure personal transmission probability. A partner-transmission trial exists for symptomatic genital HSV-2 in a selected couple population, while the cited guidelines report no corresponding suppression study for genital HSV-1. The recurrence comparison comes from an older university research-clinic cohort. Oral HSV-2 evidence is older and based on a referral/research population. The NIH source is guidance for people with HIV and is used here only for general anatomic, diagnostic, and evidence-gap statements; its treatment recommendations are not generalized. No checked source can forecast an individual's course from type alone.
Sources
- CDC. Sexually Transmitted Infections Treatment Guidelines, 2021: Genital Herpes (opens in a new tab)Return to citation
- World Health Organization. Herpes simplex virus (opens in a new tab)Return to citation
- Patel R, et al. 2024 European guidelines for the management of genital herpes (opens in a new tab)
DOI: 10.1111/jdv.20450
Return to citation - National Institutes of Health. Herpes Simplex Virus: Adult and Adolescent Opportunistic Infections (opens in a new tab)Return to citation
- Johnston C, et al. Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection (opens in a new tab)Return to citation
- Tronstein E, et al. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection (opens in a new tab)Return to citation
- Wald A, et al. Oral shedding of herpes simplex virus type 2 (opens in a new tab)Return to citation
- Benedetti JK, et al. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time (opens in a new tab)
DOI: 10.7326/0003-4819-131-1-199907060-00004
Return to citation
Browse all practical HSV guides, see how HSVHQ handles evidence and review, or report a possible correction.